Among the 6 patients who received anti-VEGF therapy, the underlying conditions were age-related macular degeneration in 1 patient (RSS 1 point), glaucoma in 1 patient (RSS 0 points), and diabetic macular edema in 4 patients (1 with RSS 2 points and 3 with RSS 3 points). This evidence concerns the gene VEGFA and diabetic macular edema.